FDA Device Intelligence
Home › Alere Scarborough, Inc. › Alere NMP22 BladderChek Test

Alere NMP22 BladderChek Test

Alere Scarborough, Inc. · Model D1300 · UDI-DI 10811877010774

NAHMMW Prescription
0
510(k) clearances
1
Adverse events
0
Recalls
4
Facilities

Description

The Alere NMP22 BladderChek Test is an in vitro immunoassay intended for the qualitative detection of the nuclear mitotic apparatus protein (NuMA) in urine of persons with risk factors or symptoms of bladder cancer or with a history of bladder cancer.

Query this across every FDA database — by API.

Linked GUDID · 510(k)/PMA · MAUDE · recalls · establishments. Free tier, no card required.

Get your free API keyRead the docs
Data compiled from public U.S. FDA sources (GUDID, 510(k)/PMA, MAUDE, recalls, establishment registration). Adverse-event reports are unverified and do not establish causation. Informational only — not medical, clinical, or regulatory advice.